This post was originally published on this site
The stock has declined 30.6% over the past three months and 9.3% over the past month to close yesterday’s trading session at $5.30.
Though the company is working through various collaborative research and projects to accelerate its growth, the stock’s bloated valuation and inadequate financial strength could make investors worried.
